Abiraterone acetate 500 mg / niraparib 100 mg [Akeega]
RxNorm 2645252

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2645252 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: abiraterone acetate 500 mg / niraparib 100 mg [Akeega].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDC
Abiraterone acetate 500 mg / niraparib 100 mg [Akeega]
AUI:12828141
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDCPrescribable

Semantic Branded Drug Component (SBDC):
Abiraterone acetate 500 mg / niraparib 100 mg [Akeega]
(Atom ID: 12828141)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
abiraterone acetate 500 MG / niraparib 100 MG [Akeega]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2645252
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12828141
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDC
Semantic Branded Drug Component (Ingredient + Strength + Brand Name)
Source Code
2645252
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Niraparib and Abiraterone


Niraparib and abiraterone is used in combination with prednisone to treat a certain type of prostate cancer that has already been treated with other medications and has spread to other parts of the body. Niraparib is in a class of medications called poly (ADP-ribose) polymerase (PARP) inhibitors. It works by killing cancer cells. Abiraterone is in a class of medications called androgen biosynthesis inhibitors. It works by decreasing the amount of certain hormones in the body.
[Learn More]


* Please review the disclaimer below.